Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients (EURELIA1)

NCT05586958 PHASE3 COMPLETED

The aim of this 6-month randomized multi-regional double-blind parallel group placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.

Details

Lead sponsor	LG Chem
Phase	PHASE3
Status	COMPLETED
Enrolment	354
Start date	Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Dec 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Gout
• Hyperuricemia
• Gout Flare
• Tophi

Interventions

• Tigulixostat
• Placebo

Countries

Georgia, Philippines, Thailand, United States